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Oxytocin is stored and released by the posterior pituitary gland. In this study, the influence of 
oxytocin agonist, demoxytocin pretreatment on the behavioural actions of melatonin was 
ascertained. Swiss albino mice (n=6) were used for this study as control and test groups. 
Demoxytocin was injected in a concentration of (20 I.U/kg, i.p) and melatonin was injected 
(200μg/kg, i.p) 30 minutes before experimentation. The effect of pretreatment with 
demoxytocin was evaluated after melatonin injection on motor-coordination and locomotor 
activity. The results of our study suggest that demoxytocin was not able to affect significantly 
the actions on motor co-ordination but attenuated the locomotor activity after melatonin 
treatment. 
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Introduction 
Oxytocin  has been shown to have a role in social 
separation and related stress. Oxytocin serves important roles 
in behaviour regulation and plays important role in emotional 
and social bonding (Landgraf, 1995). Oxytocin receptor is 
expressed in the central nervous system and is a G protein 
coupled receptor. Demoxytocin also known as deamino-
oxytocin is an agonist of oxytocin with almost similar profile but 
some difference in pharmacokinetics and affinity for the 
oxytocin receptor. The effects of demoxytocin on behavioural 
aspects have not been studied well and there are few 
documented reports. On the other hand, melatonin is a 
ubiquitous natural neurotransmitter like compound and 
released by the pineal gland. Melatonin has been shown to 
modify the stress response and aging process and regulates a 
variety of physiological and neuroendocrine functions through 
activation of G protein coupled receptors in target tissues 
(Dubocovich, 1995). Melatonin is expressed in the brain 
(Cardinali, 1981) and has multifaceted roles in physiology of 
circadian rhythm (Al-Ghoul, 1998). In this study, we have 
evaluated the influence of oxytocin agonist, demoxytocin on 
the motor coordination and open field locomotor activity in mice 
after treatment with melatonin. 
Materials and Methods  
Experiments were performed on Swiss albino mice 
weighing 25-35g and belonging to either sex. They were 
obtained from Institutional Animal Centre of Christian Medical 
College, Vellore, India. Animals were divided into groups of 6-8 
and kept in separate polypropylene plastic cages under 
hygienic conditions, lined with paddy-husk bedding. These 
animals were housed in a colony room under controlled 
temperature (25±1ºc), relative humidity of (60±2%) and were 
exposed to a 12-h dark cycle, with food and water available ad 
libitum. All experiments were conducted during the light phase 
between 9.00 a.m. and 4.00 p.m. The experimental protocol 
was approved by the Institutional Review Board (IRB) and care 
of animals was taken as per guidelines of CPCSEA, 
Department of Animal Welfare, Government of India.  
Drugs and Chemicals 
Melatonin tablets were obtained from Aristo 
Pharmaceuticals Pvt. Ltd., Nani Daman, Daman (U.T) and 
demoxytocin tablets (Sandoz Pharma.,Switzerland) were 
obtained from a local pharmacy store. 0.9 % Saline was 
obtained from CMCH pharmacy, Vellore. 
Methods  
A) Rota-rod Test (Motor Co-ordination in mice): Rota-rod 
test is often used with the apparent assumption by the 
experimenters that it is a straightforward and simple assay of 
motor coordination. A Rota-rod tread mill device (Inco, India) 
was used for the evaluation of the effect of drugs on the motor 
coordination at speed of 20 rotations per minute. Twenty 
minutes after administration of demoxytocin (20 IU/kg) i.p and 
later 30 minutes after melatonin (200μg/kg) i.p was injected. 
Each mouse was placed on the rotating rod for 5 min (300 
secs). The endurance time for each mouse i.e the time mice 
fell of from the rota rod  was noted. 
B) Loco-motor Activity Test: The loco-motor activity of 
albino mice weighing between 25- 35 g were evaluated in an 
open field loco-motor box made of wood with dimensions 
(24×24×5) inch and comprising of 16 squares. Loco-motor 
activity was estimated visually counting the no. of squares the 
animals crossed in 6 mins. Mice were injected with one of the 
test drugs or its vehicle and were placed in holding cage for 20 
minutes for demoxytocin and 30 minutes for melatonin before 
testing. Each animal was tested once for the loco-motor activity 
(Tyagi and Jose, 1999). 
 




C) Statistical Analysis: For statistical evaluation of results 
and significance testing of group differences, the 
nonparametric Mann-Whitney U-test and Wilcoxon W test was 
performed. Results were considered to be of statistical 
significance at P≤0.05 (95% confidence interval). Data are 
presented as Means ± S.E.M. 
Results 
The results of our study are depicted in Table 1 and Table 
2. As depicted in the Table 1, pretreatment with demoxytocin 
(20 IU/kg i.p) caused a substantial decrease in locomotor 
activity following treatment with melatonin (28.93 %) and this 
was found to be statistically significant. On the other hand 
pretreatment with demoxytocin did not significantly affect motor 
co-ordination following melatonin treatment as depicted in 
Table 2. 
 
Table 1: Effect of demoxytocin and melatonin on the locomotor activity in mice. * denotes the significant values (P<0.05). 
Pretreatment  Treatment 
Locomotor 
Activity  % Change 
Saline Saline 99.2 ± 4.9  
Saline Demoxytocin 76.6 ± 3.7 22.78* 
Saline Melatonin 89.8 ± 7.3 9.47 
Demoxytocin Melatonin 70.5 ± 5.6 28.93* 
 
Table 2: Effect of demoxytocin and melatonin on the motor co-ordination in mice. 
Pretreatment Treatment 
Fall of time 
(Secs) % Change 
Saline Saline 95.8 ± 3.7  
Saline  Demoxytocin 84.2 ± 5.8 12.10 
Saline  Melatonin 86.1 ± 6.3 10.12 
Demoxytocin Melatonin 83.7 ± 7.1 12.63 
    
Discussion   
Demoxytocin is a synthetic analogue of oxytocin used 
orally for induction of labour. It has a difference in its biological 
potency although many of its biological effects are similar to 
oxytocin (Gazis et al, 1980). We treated the animals with 
demoxytocin injections and also in combination with melatonin. 
The results of our study are depicted in Table 1 & 2. As it is 
clear from Table  2, demoxytocin did not appreciably affect the 
motor coordination although it did affect locomotor activity 
suggesting some central role in the oxytocinergic 
neurons/receptors in the brain (Urry, 1987). On the other hand, 
melatonin, the main hormone secreted by the pineal gland, 
mediates a variety of cellular, neuroendocrine and 
physiological processes; besides, melatonin displays through 
different mechanisms a protective role against damage caused 
by free radicals (Shaji & Kulkarni, 1998; Reiter, 1995). After 
systemic administration, melatonin crosses rapidly the blood–
brain barrier and is distributed to the cerebrospinal fluid and 
throughout the different regions of the brain (Vitte et al., 1988). 
Melatonin was able to affect the locomotor activity and motor 
co-ordination more potently, based on our results and this can 
be attributed to the inhibitory effects in the hippocampus and 
synaptic potentiation in dorsal horn of spinal cord (Ruben Soto 
Moyano et al 2006). A role for GABAergic mechanism has 
been speculated for these effects (McNamara, 1996). 
Demoxytocin does not affect the motor coordination and was 
ineffective in modulating the actions of melatonin thus 
suggesting a lesser affinity for oxytocin receptors then its 
parent compound i.e oxytocin.  
Thus this study implicates that the ability of melatonin to 
modulate neuronal activity may account for many of its 
physiological actions of melatonin on the central nervous 
system, it is also conceivable that magnification of these 
effects when higher, pharmacological doses of the hormone 
are administered, could result in altered function of some 
central neurons such as those involved in long-term synaptic 
potentiation but it can be safely co-administered with oxytocin 
analogues in a possible clinical scenario. 
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